agomelatine
Trade name: Valdoxan
Agomelatine, sold under the brand names Valdoxan and Thymanax, among others, is an atypical antidepressant most commonly used to treat major depressive disorder and generalized anxiety disorder. One review found that it is as effective as other antidepressants with similar discontinuation rates overall but fewer discontinuations due to side effects. Another review also found it was similarly effective to many other antidepressants. — Wikipedia
Clinical trial activity
22 trials · 18 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 2006 (NCT00451490)
Timeline
Indications
Approved for
Studied for
- Anxiety Disorders · Phase 3
- Chronobiology Disorders · Phase 4
- Dementia · Phase 3
- Depression · Phase 4
- Depressive Disorder, Treatment-Resistant · Phase 3
- Ischemic Stroke · Phase 4
- Kidney Failure, Chronic · Phase 1
- Liver Diseases · Phase 1/Phase 2
- Major Depressive Disorder · Phase 4
- Obsessive-Compulsive Disorder · Phase 2
- Parkinson Disease · Phase 4
- Psychophysiologic Disorders · Phase 3
- Psychotic Disorders · Phase 4
- Schizophrenia · Phase 4
- Schizophrenia, Paranoid · Phase 4
- Sleep Wake Disorders · Phase 4
Mechanism of action
- Melatonin receptorAGONIST
Melatonin receptor agonist
Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors.
Melatonin receptor MT1, Ki=0.1nM / MT2, Ki=0.12nM 5-HT2C receptor, Ki=631nM
- Serotonin 2c (5-HT2c) receptorANTAGONIST
HTR2C antagonist
Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors.
Melatonin receptor MT1, Ki=0.1nM / MT2, Ki=0.12nM 5-HT2C receptor, Ki=631nM
Chemistry & pharmacology
SMILES
COc1ccc2cccc(CCNC(C)=O)c2c1- Mol. weight
- 243.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaAgomelatine ↗
- ChEMBLCHEMBL10878 ↗
Also known as
- ago178
- ago178
- ago178
- ago 178
- ago-178
- agomelatine
- agomelatine
- agomelatine
- agomelatine
- agomelatine
- agomelatine
- agomelatine
- agomelatine
- agomelatine
- agomelatine
- n-(2-(7-methoxy-1-naphthyl)ethyl)acetamide
- s20098
- s20098
- s20098
- s20098
- s20098
- s20098
- s 20098
- s-20098
- s-20098
- thymanax
- thymanax
- valdoxan
- valdoxan
- valdoxan
- valdoxan
- valdoxan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07011693 | Phase 4 | Jun 20, 2025 | Chongqing Medical University |
| NCT05646264 | Phase 4 | Jan 1, 2023 | Jiao Tong University, Tianjin Medical University |
| NCT05426304 | Phase 4 | Oct 1, 2022 | Sun Yat-Sen University |
| NCT04589143 | Phase 4 | Oct 1, 2020 | Central South University |
| NCT03977441 | Phase 4 | Jul 31, 2019 | Soochow University |
| NCT03852160 | Phase 3 | May 22, 2019 | Johnson and Johnson |
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
| NCT04181567 | Phase 4 | Mar 3, 2014 | Government of Taiwan, Kaohsiung Medical University |
| NCT01483053 | Phase 4 | Jan 1, 2014 | Monash University, Servier, The Alfred Hospital |
| NCT01822418 | Phase 4 | Jan 1, 2013 | Servier, University of Heidelberg |
| NCT01488071 | Phase 3 | Jan 1, 2012 | Lundbeck |
| NCT01459250 | Phase 1 | Mar 1, 2011 | Novartis |
| NCT01531309 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2011 | Novartis, Servier |
| NCT01156415 | Phase 3 | Jun 1, 2010 | Novartis |
| NCT01108393 | Phase 2 | May 1, 2010 | Servier, Tel Aviv University |
| NCT01110902 | Phase 3 | May 1, 2010 | Novartis |
| NCT01110889 | Phase 3 | May 1, 2010 | Novartis |
| NCT00467402 | Phase 3 | Apr 1, 2007 | Novartis |
| NCT00463242 | Phase 3 | Mar 1, 2007 | Novartis |
| NCT00411242 | Phase 3 | Dec 1, 2006 | Novartis |
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 9 | 9 | 3 | 2006 |
| Servier | For profit | 4 | 1 | 2 | 2010 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Chongqing Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Government of Taiwan | Government | 1 | 0 | 1 | 2014 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2019 |
| Kaohsiung Medical University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Lundbeck | For profit | 1 | 1 | 1 | 2012 |
| Monash University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| National Taiwan University | Academic/Hospital | 1 | 1 | 1 | 2006 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| The Alfred Hospital | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Heidelberg | Academic/Hospital | 1 | 1 | 1 | 2013 |